Hepatitis Viruses Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: October 15, 2021 Report Code: GDME1208EPD-ST

Select Item

Hepatitis Viruses Rapid Tests & POC comprises of rapid test kits intended for rapid diagnosis, with immediate results, through immuno assays for Hepatitis B and C. GlobalData’s Medical Devices sector report, “Hepatitis Viruses Rapid Tests & POC – Medical Devices Pipeline Product Landscape, 2021″ provides comprehensive information about the Hepatitis Viruses Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

The Hepatitis Viruses Rapid Tests & POC report provides key information and data related to:
Extensive coverage of the Hepatitis Viruses Rapid Tests & POC under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths, and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Hepatitis Viruses Rapid Tests & POC pipeline products.
Review of Recent Developments in the segment / industry
The Hepatitis Viruses Rapid Tests & POC report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Hepatitis Viruses Rapid Tests & POC under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
• 64,000+ medical equipment company profiles
• 5,600+ company profiles of medical equipment manufacturers in China and India
• 2,200+ company profiles of medical equipment manufacturers in Japan
• 1,200+ companies’ revenue splits and market shares
• 1,600+ quarterly and annual medical equipment company financials
• 850+ medical equipment company SWOTs
• 28,000+ pipeline product profiles
• 56,400+ marketed product profiles
• 47,000+ clinical trials
• 41,500+ trial investigators
• 7,000+ reports on companies with products in development
• 44,000+ deals in the medical equipment industry
• 1,100+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
• 431,000+ Themes Content Items
• 600+ Influencers
• 1,900+ Analysts & Researchers
• 0.5m+ Community Members
• 141,000+ Macroeconomic Indicators
• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

– Extensive coverage of the Hepatitis Viruses Rapid Tests & POC under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Hepatitis Viruses Rapid Tests & POC and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage

– Identify and understand important and diverse types of Hepatitis Viruses Rapid Tests & POC under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Bigtec Pvt Ltd
Biocartis Group NV
bioLytical Laboratories Inc
Biotech Resources Aust Pty Ltd
Daktari Diagnostics, Inc.
Diagnostics for the Real World Ltd
Group K Diagnostics
ImmunoScience Inc
MedMira Inc
MyMD Pharmaceuticals, Inc
NanoRepro AG
Wave 80 Biosciences Inc

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 6

2 Introduction 7

2.1 Hepatitis Viruses Rapid Tests & POC Overview 7

3 Products under Development 8

3.1 Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Stage of Development 8

3.2 Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Territory 9

3.3 Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Regulatory Path 10

3.4 Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Estimated Approval Date 11

4 Hepatitis Viruses Rapid Tests & POC – Pipeline Products under Development by Companies 12

4.1 Hepatitis Viruses Rapid Tests & POC Companies – Pipeline Products by Stage of Development 12

4.2 Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Stage of Development 13

5 Hepatitis Viruses Rapid Tests & POC Companies and Product Overview 14

5.1 Bigtec Pvt Ltd Company Overview 14

5.1.1 Bigtec Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 14

5.2 Biocartis Group NV Company Overview 15

5.2.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 15

5.3 bioLytical Laboratories Inc Company Overview 16

5.3.1 bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 16

5.4 Biotech Resources Aust Pty Ltd Company Overview 17

5.4.1 Biotech Resources Aust Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

5.5 Daktari Diagnostics, Inc. Company Overview 18

5.5.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18

5.6 Diagnostics for the Real World Ltd Company Overview 19

5.6.1 Diagnostics for the Real World Ltd Pipeline Products & Ongoing Clinical Trials Overview 19

5.7 Group K Diagnostics Company Overview 20

5.7.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20

5.8 ImmunoScience Inc Company Overview 22

5.8.1 ImmunoScience Inc Pipeline Products & Ongoing Clinical Trials Overview 22

5.9 MedMira Inc Company Overview 24

5.9.1 MedMira Inc Pipeline Products & Ongoing Clinical Trials Overview 24

5.10 MyMD Pharmaceuticals, Inc Company Overview 25

5.10.1 MyMD Pharmaceuticals, Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.11 NanoRepro AG Company Overview 26

5.11.1 NanoRepro AG Pipeline Products & Ongoing Clinical Trials Overview 26

5.12 Wave 80 Biosciences Inc Company Overview 27

5.12.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 27

6 Hepatitis Viruses Rapid Tests & POC- Recent Developments 29

6.1 Oct 12, 2021: Quotient Announces Appointment of Chief Financial Officer 29

6.2 Oct 05, 2021: Quotient Announces Appointment of Chief Commercial Officer 29

6.3 Oct 04, 2021: Quotient Announces Appointment of New Chief Scientific & Medical Officer 30

6.4 Sep 28, 2021: Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28 31

6.5 Sep 23, 2021: Biocartis announces restart of its high-throughput cartridge manufacturing line 31

6.6 Sep 01, 2021: Quotient Announces Christian Albrich as Chief People Officer 31

6.7 Aug 17, 2021: Second update on fire incident at Biocartis warehouse 32

6.8 Aug 11, 2021: Quotient Announces Departure of Chief Commercial Officer, Jeremy Stackawitz 33

6.9 Aug 05, 2021: Quotient Provides First Quarter Fiscal 2022 Results and Business Update 33

6.10 Jul 29, 2021: Merck Announces Second-Quarter 2021 Financial Results 35

6.11 Jul 02, 2021: Quotient Announces Departure of Chief Financial Officer, Peter Buhler 38

6.12 Apr 29, 2021: Merck Announces First-Quarter 2021 Financial Results 38

6.13 Mar 29, 2021: Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29 39

6.14 Mar 25, 2021: Genedrive Announces unaudited interim results for the six months to 31 December 2020 39

6.15 Mar 22, 2021: Akers Biosciences announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals 40

6.16 Mar 03, 2021: Merck to Present at the Barclays Global Healthcare Conference 40

6.17 Feb 24, 2021: Merck to Present at the Cowen 41st Annual Health Care Conference 40

6.18 Feb 24, 2021: Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference 41

6.19 Feb 18, 2021: Press news Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 FULL YEAR RESULTS ON 25 FEBRUARY 2021 41

6.20 Feb 12, 2021: Quotient Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference 42

6.21 Feb 05, 2021: Merck CFO Brings Corporate Strategy Experience to CEO Role 42

6.22 Jan 19, 2021: Quotient to Report Third Quarter 2021 Financial Results and Host Conference Call 42

7 Appendix 43

7.1 Methodology 43

7.2 About GlobalData 46

7.3 Contact Us 46

Table

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Stage of Development 8

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Territory 9

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Regulatory Path 10

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Estimated Approval Date 11

Hepatitis Viruses Rapid Tests & POC Companies – Pipeline Products by Stage of Development 12

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Stage of Development 13

Bigtec Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 14

Rapid Diagnostic Test – HBV/HCV – Product Status 14

Rapid Diagnostic Test – HBV/HCV – Product Description 14

Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 15

Idylla Viral Load Assay – HCV – Product Status 15

Idylla Viral Load Assay – HCV – Product Description 15

bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 16

INSTI HCV Antibody Test – Product Status 16

INSTI HCV Antibody Test – Product Description 16

Biotech Resources Aust Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 17

ATR-FTIR System – Hepatitis B & C – Product Status 17

ATR-FTIR System – Hepatitis B & C – Product Description 17

Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18

Daktari HCV POC System – Product Status 18

Daktari HCV POC System – Product Description 18

Diagnostics for the Real World Ltd Pipeline Products & Ongoing Clinical Trials Overview 19

Point-Of-Care NAAT Assay – Product Status 19

Point-Of-Care NAAT Assay – Product Description 19

Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20

Multidiagnostic – Hepatitis A-D Virus Test – Product Status 20

Multidiagnostic – Hepatitis A-D Virus Test – Product Description 20

Multidiagnostic – Hepatitis Load Test – Product Status 21

Multidiagnostic – Hepatitis Load Test – Product Description 21

ImmunoScience Inc Pipeline Products & Ongoing Clinical Trials Overview 22

Salivax – Hepatitis B – Product Status 22

Salivax – Hepatitis B – Product Description 22

Salivax-HCV – Product Status 23

Salivax-HCV – Product Description 23

MedMira Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Reveal HBsAg Rapid Test – Product Status 24

Reveal HBsAg Rapid Test – Product Description 24

MyMD Pharmaceuticals, Inc Pipeline Products & Ongoing Clinical Trials Overview 25

PIFA Hep B / Hep C – Product Status 25

PIFA Hep B / Hep C – Product Description 25

NanoRepro AG Pipeline Products & Ongoing Clinical Trials Overview 26

Rapid Diagnostic Test – Hepatitis B+C – Product Status 26

Rapid Diagnostic Test – Hepatitis B+C – Product Description 26

Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 27

EOSCAPE-HBV DNA – Product Status 27

EOSCAPE-HBV DNA – Product Description 27

EOSCAPE-HCV RNA – Product Status 28

EOSCAPE-HCV RNA – Product Description 28

Figures

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Stage of Development 8

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Territory 9

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Regulatory Path 10

Hepatitis Viruses Rapid Tests & POC – Pipeline Products by Estimated Approval Date 11

Frequently asked questions

Hepatitis Viruses Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Hepatitis Viruses Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
New
PTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region…
$4,000 | March 2024
Medical Devices
New
Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Medical Devices
New
PCR Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed…
$7,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hepatitis Viruses Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 in real time.

  • Access a live Hepatitis Viruses Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more